Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2024

Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, et al. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Cancer Lett. 2024;584:216608.

Venkadakrishnan VB, Presser AG, Singh R, Booker MA, Traphagen NA, Weng K, et al. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Res Sq. 2024.

Hoellwarth JS, Reif TJ, Mori S, Kang R, Magro CM. Horrifying Basal Cell Carcinoma Presenting as Progressive Pyoderma Gangrenosum: Case Report. Case Rep Oncol. 2024;17(1):298-304.

Jain D, Khandakar B, Ni P, Kenney B, Qin L, Deshpande V, et al. von Meyenburg complexes are more frequently associated with cholangiocarcinoma. J Clin Pathol. 2024.

Myint O, Sakunrangsit N, Pholtaisong J, Toejing P, Pho-On P, Leelahavanichkul A, et al. Differential Gene Expression Involved in Bone Turnover of Mice Expressing Constitutively Active TGFβ Receptor Type I. Int J Mol Sci. 2024;25(11).

Galbraith K, Serrano J, Shen G, Tran I, Slocum CC, Ketchum C, et al. Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain Tumors. Mol Cancer Res. 2024;22(1):21-28.

Hu S, Graham RP, Choi W-, Wen KW, Putra J, Chen W, et al. Clinicopathologic Features of Gastrointestinal Tract Langerhans Cell Histiocytosis. Mod Pathol. 2024;37(9):100543.

Ohara K, Rendeiro AF, Bhinder B, Eng KW, Ravichandran H, Nguyen D, et al. The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis. Nat Commun. 2024;15(1):2009.

Daman AW, Antonelli AC, Redelman-Sidi G, Paddock L, Cheong JG, Jurado LF, et al. Microbial cancer immunotherapy reprograms hematopoietic stem cells to enhance anti-tumor immunity. bioRxiv. 2024.

Hsu H, Zanettini C, Coker M, Boudova S, Rach D, Mvula G, et al. Concomitant assessment of PD-1 and CD56 expression identifies subsets of resting cord blood Vδ2 T cells with disparate cytotoxic potential. Cell Immunol. 2024;395-396:104797.